Keyphrases
Androgen-independent
100%
Phase II Trial
100%
Etoposide
100%
Estramustine
100%
Metastatic Prostate Carcinoma
100%
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
75%
Measurable Disease
50%
Anemia
25%
Median Survival
25%
Newly Diagnosed
25%
Organ Function
25%
Nineteen
25%
Severe Toxicity
25%
Gleason Score
25%
Performance Status
25%
Objective Response
25%
Dose Reduction
25%
Overall Survival Rate
25%
3-cycle
25%
Febrile Neutropenia
25%
Median Time
25%
6-cycles
25%
PSA Level
25%
Hormonal Therapy
25%
Visceral Metastases
25%
Bone-only Metastasis
25%
Hormone-sensitive Metastatic Prostate Cancer
25%
PSA Progression
25%
Chemohormonal Therapy
25%
PSA Nadir
25%
Pharmacology, Toxicology and Pharmaceutical Science
Etoposide
100%
Phase II Trials
100%
Prostate Cancer
100%
Prostate Carcinoma
100%
Estramustine
100%
Androgen
100%
Diseases
50%
Hormone Cancer Therapy
25%
Overall Survival
25%
Survival Rate
25%
Thromboembolism
25%
Gleason Score
25%
Visceral Metastasis
25%
Anemia
25%
Febrile Neutropenia
25%